Neurona Therapeutics’ Post

On Friday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here:

Yesterday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here: https://lnkd.in/gXJvqA-s

Today, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here: https://lnkd.in/gXJvqA-s

On Friday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE.

Current Indications and Challenges for CAR-T Therapy in Earlier Lines CAR-T cell therapy, initially reserved for last-line treatment, is now being explored and approved for earlier lines of therapy in various hematologic malignancies.

Calling all #lupus specialists & researchers: The March edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month, we delve into topics such as the efficacy of #CAR-T cell therapy, the role of #belimumab in treating childhood-onset #SLE, and the latest in #SLE diagnosis: https://lnkd.in/euBZmUb7

How can manufacturers develop workflows to deliver highly individualized cell therapy products while developing processes that can deliver scalable treatments? Master tumor infiltrating lymphocyte therapy manufacturing with this recourse from Cytiva. Download now >>> https://hubs.ly/Q02pMpdk0

⏰ Save The Date - 27th June ⏰ Join our upcoming webinar featuring a panel discussion on methods of streamlining the CAR-T workflow. As CAR-T cell therapy continues to advance it's important to address the challenges that come with it. One key issue is the manufacturing process, which can be costly and time-consuming. That's why efforts to create a more efficient CAR-T cell therapy manufacturing process are crucial. Join this webinar to learn more about the analytical tools that are contributing to these advancements! #celltherapy #CART

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy #CellReportsMedicine https://hubs.li/Q02rpCKX0

We’re 🤯 by the latest clinical trial research from Oncologie | UNIL-CHUV! Read our blog to see how they used #singlecell technologies to characterize the tumor-immune features that could be the key to successful adoptive cell therapy in metastatic #melanoma.